Long-term outcome of immunologic autograft engineering

Area of Science:

• Hematology
• Transplantation Immunology
• Oncology

Background:

• Autologous peripheral blood hematopoietic stem cell transplantation (APBHSCT) is a critical treatment modality.
• Previous short-term studies indicated autograft-absolute lymphocyte count (A-ALC) improves survival post-APBHSCT.
• Long-term survival benefits of A-ALC require further investigation.

Purpose of the Study:

• To retrospectively evaluate the long-term survival benefit of A-ALC post-APBHSCT.
• To determine if A-ALC confers a sustained survival advantage with extended follow-up.
• To analyze the impact of A-ALC on overall survival and progression-free survival.

Main Methods:

• Retrospective analysis of patients from a phase III trial.
• Evaluation of A-ALC levels in infused grafts.
• Statistical analysis of overall survival and progression-free survival with a median follow-up of 127.6 months.

Main Results:

• Patients with A-ALC ≥ 0.5 × 10⁹ cells/kg demonstrated significantly better overall survival (HR = 0.392, p < 0.001).
• Progression-free survival was also significantly improved in patients with higher A-ALC levels (HR = 0.413, p < 0.0004).
• The survival benefit associated with A-ALC was sustained over a long-term follow-up period.

Conclusions:

• A-ALC is a significant predictor of long-term survival post-APBHSCT.
• Maintaining adequate A-ALC levels is crucial for optimizing patient outcomes.
• This study confirms the enduring survival advantage conferred by A-ALC in APBHSCT recipients.